si:dkey-20i6.3 Antibody

What is si:dkey-20i6.3 and why is it significant in zebrafish research?

Si:dkey-20i6.3 is a gene in zebrafish (Danio rerio) that encodes a homolog of the human UPF0472 protein C16orf72. The protein has several alternative identifiers including zgc:77849, fb59e09, zgc:56060, and wu:fb59e09, which reflects its identification through different genomic approaches . This protein is particularly significant in zebrafish research as a model for understanding the function of conserved uncharacterized proteins across vertebrates. The "UPF" designation indicates an uncharacterized protein family, suggesting that while the protein has been identified, its precise function remains to be fully elucidated. Studying this protein in zebrafish can provide valuable insights into the function of its human homolog.

What types of antibodies are available for si:dkey-20i6.3 detection?

Currently, the primary antibody available for si:dkey-20i6.3 detection is a rabbit polyclonal antibody specifically generated against Danio rerio si:dkey-20i6.3 . This antibody has been purified using antigen-affinity methods to ensure specificity. Unlike the mouse monoclonal antibodies used for targets like MYH1E (MF 20) , the polyclonal nature of the si:dkey-20i6.3 antibody means it recognizes multiple epitopes on the target protein, which can increase detection sensitivity but may also increase the potential for cross-reactivity. The antibody's isotype is IgG, making it compatible with standard secondary antibody detection systems .

What are the validated applications for si:dkey-20i6.3 antibody in zebrafish research?

The si:dkey-20i6.3 antibody has been validated for several key applications in zebrafish research:

• Western Blot (WB): The antibody has been confirmed to detect the native and denatured forms of the protein in zebrafish tissue lysates . For optimal results, researchers should use standard SDS-PAGE protocols with reducing conditions.

• Enzyme-Linked Immunosorbent Assay (ELISA): The antibody is effective in plate-based immunoassays for quantitative detection of the target protein .

When designing experiments, researchers should note that unlike some extensively characterized antibodies like MF 20 (which has been validated for ELISA, FACS, FFPE, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, and Western Blot) , the si:dkey-20i6.3 antibody has more limited validated applications. Research protocols should therefore include appropriate controls to confirm specificity in the experimental context.

How should I optimize Western blot conditions for si:dkey-20i6.3 detection?

For optimal Western blot detection of si:dkey-20i6.3:

• Sample preparation: Extract proteins from zebrafish tissues using standard lysis buffers containing protease inhibitors. For developmental studies, consider using stage-specific embryos or larvae.

• Gel selection: Use 10-12% polyacrylamide gels for effective separation.

• Transfer conditions: Use PVDF membranes for optimal protein binding.

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute the si:dkey-20i6.3 antibody at 1:500 to 1:1000 in blocking solution. Incubate overnight at 4°C.

• Secondary antibody: Use anti-rabbit IgG HRP-conjugated secondary antibody at 1:5000 dilution.

• Detection: Use enhanced chemiluminescence (ECL) for visualization.

Since this protein is not as well-characterized as some commonly studied proteins like myosin heavy chain , optimization steps should include a range of antibody dilutions and extended exposure times if initial results are weak.

How does si:dkey-20i6.3 expression compare with other zebrafish genes using antibody-based detection methods?

When comparing si:dkey-20i6.3 expression with other zebrafish genes, researchers should consider both spatial and temporal expression patterns. Unlike well-characterized structural proteins such as myosin heavy chain (detected by MF 20 antibody) , which shows distinctive expression in muscle tissues, the expression pattern of si:dkey-20i6.3 is less defined in the literature.

For comparative analysis:

• Multi-label immunofluorescence: Combine si:dkey-20i6.3 antibody with antibodies against tissue-specific markers to determine co-localization patterns.

• Developmental time-course: Analyze expression at different developmental stages from early embryos to adult tissues.

• Quantitative comparison: Use Western blot densitometry to compare expression levels across tissues or developmental stages.

Single-cell RNA sequencing approaches, similar to those used in recent zebrafish immunology studies , can provide complementary data on gene expression patterns at the transcriptional level.

What is known about si:dkey-20i6.3 homology with human C16orf72, and how can antibodies help explore functional conservation?

Si:dkey-20i6.3 is the zebrafish homolog of human UPF0472 protein C16orf72 . This homology presents an opportunity to study evolutionary conservation of protein function. To explore functional conservation using antibodies:

• Cross-reactivity testing: Determine if the zebrafish-specific antibody recognizes the human homolog. This can indicate structural conservation of epitopes.

• Subcellular localization studies: Compare localization patterns in zebrafish and human cells using immunofluorescence.

• Protein-protein interaction studies: Use co-immunoprecipitation with the si:dkey-20i6.3 antibody to identify interacting partners and compare with known human C16orf72 interactions.

• Functional rescue experiments: In knockdown/knockout studies, determine if human C16orf72 can rescue zebrafish phenotypes, and use the antibody to confirm expression of the rescue construct.

This comparative approach can provide insights into conserved functions across vertebrate evolution, similar to how antibody studies have illuminated evolutionary conservation in immune proteins .

How can I use si:dkey-20i6.3 antibody in CRISPR-Cas9 gene editing validation studies?

When using CRISPR-Cas9 to target si:dkey-20i6.3 in zebrafish, antibody-based validation is crucial:

• Knockout verification: Use Western blot with the si:dkey-20i6.3 antibody to confirm protein loss in CRISPR-edited fish. This is particularly important since genomic edits may not always result in complete protein loss.

• Mosaic analysis: In F0 injected embryos, immunostaining can reveal mosaicism in protein expression, helping to select appropriate founders.

• Off-target effect assessment: Compare expression patterns of related proteins to ensure specificity of gene editing.

• Truncation verification: For experiments designed to create truncated proteins, use the antibody to confirm the size and expression level of the modified protein.

Include appropriate controls such as wild-type siblings and samples from established null mutants if available.

What approaches can I use to resolve contradictory results between antibody detection and mRNA expression data for si:dkey-20i6.3?

Discrepancies between protein detection using si:dkey-20i6.3 antibody and mRNA expression data are not uncommon and can provide insights into post-transcriptional regulation. To address such contradictions:

• Temporal analysis: Examine whether differences reflect time delays between transcription and translation by sampling at multiple time points.

• Protein stability assessment: Use cycloheximide chase experiments with Western blot detection to determine protein half-life.

• Subcellular fractionation: Determine if the protein localizes to specific cellular compartments that might complicate whole-cell or whole-tissue detection.

• Antibody validation: Perform additional specificity tests, such as detection in knockout/knockdown samples or preabsorption with recombinant protein.

• Cross-validation with epitope tags: Create transgenic lines expressing tagged versions of si:dkey-20i6.3 and compare antibody detection of the endogenous protein with tag-based detection.

This multifaceted approach can help determine whether discrepancies represent biological regulation or technical limitations.

What is the optimal protocol for immunoprecipitating si:dkey-20i6.3 and its binding partners?

While the si:dkey-20i6.3 antibody has not been explicitly validated for immunoprecipitation , polyclonal antibodies often work well for this application. For an optimized immunoprecipitation protocol:

• Lysis buffer optimization: Use a gentle lysis buffer (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, with protease inhibitors) to maintain protein interactions.

• Antibody coupling: Pre-couple the si:dkey-20i6.3 antibody to Protein A/G beads (3-5 μg antibody per 50 μl bead slurry) for 1 hour at room temperature.

• Pre-clearing: Pre-clear lysates with bare beads to reduce non-specific binding.

• Immunoprecipitation: Incubate pre-cleared lysates with antibody-coupled beads overnight at 4°C with gentle rotation.

• Washing: Perform at least 4 washes with decreasing salt concentrations to remove non-specific interactions while preserving specific ones.

• Elution: Elute with glycine buffer (pH 2.5) or SDS sample buffer, depending on downstream applications.

• Analysis: Analyze by Western blot or mass spectrometry to identify interacting partners.

For cross-linking immunoprecipitation to capture transient interactions, consider using DSP (dithiobis[succinimidyl propionate]) before cell lysis.

How can I validate the specificity of interactions detected using si:dkey-20i6.3 antibody in co-immunoprecipitation experiments?

To validate the specificity of protein interactions detected in co-immunoprecipitation experiments:

• Reverse immunoprecipitation: Perform reciprocal co-IP using antibodies against the identified interacting partners.

• Negative controls: Include IgG-matched control antibodies and lysates from si:dkey-20i6.3 knockout/knockdown samples.

• Competition assays: Pre-incubate the antibody with recombinant si:dkey-20i6.3 protein before immunoprecipitation to block specific binding.

• Stringency tests: Perform immunoprecipitation under increasing salt or detergent concentrations to distinguish robust from weak interactions.

• Domain mapping: Create truncated versions of si:dkey-20i6.3 to identify specific interaction domains.

• In vivo validation: Use techniques like proximity ligation assay (PLA) or FRET to confirm proximity of proteins in intact cells.

These validation steps are particularly important for previously uncharacterized proteins like si:dkey-20i6.3, where interaction networks have not been extensively mapped.

What is the optimal fixation and immunohistochemistry protocol for si:dkey-20i6.3 detection in zebrafish tissues?

Although not explicitly validated for immunohistochemistry , the following protocol can be adapted for si:dkey-20i6.3 detection in zebrafish tissues:

• Fixation: Fix embryos or adult tissues in 4% paraformaldehyde in PBS for 24 hours at 4°C (adjust fixation time based on tissue size).

• Processing and sectioning:

  • For paraffin sections: Dehydrate, clear, and embed in paraffin. Cut 5-7 μm sections.

  • For cryosections: Cryoprotect in 30% sucrose, embed in OCT compound, and cut 10-12 μm sections.

• Antigen retrieval: For paraffin sections, use citrate buffer (pH 6.0) at 95°C for 20 minutes.

• Blocking: Block with 5% normal goat serum, 1% BSA, 0.1% Triton X-100 in PBS for 1 hour at room temperature.

• Primary antibody: Incubate with si:dkey-20i6.3 antibody (1:200 to 1:500 dilution) overnight at 4°C.

• Secondary antibody: Use fluorescent or HRP-conjugated anti-rabbit secondary antibody (1:500 dilution) for 1-2 hours at room temperature.

• Detection: For fluorescent detection, counterstain with DAPI. For HRP detection, develop with DAB and counterstain with hematoxylin.

• Controls: Include sections from si:dkey-20i6.3 knockdown/knockout fish and primary antibody omission controls.

This protocol may require optimization for different developmental stages or tissue types.

How does si:dkey-20i6.3 expression compare across different developmental stages in zebrafish?

A comprehensive developmental expression analysis for si:dkey-20i6.3 using the specific antibody would include:

• Developmental time course: Analyze protein expression at key developmental stages:

  • Early cleavage (0-2 hpf)

  • Blastula (2.5-5 hpf)

  • Gastrula (5.5-10 hpf)

  • Segmentation (10-24 hpf)

  • Pharyngula (24-48 hpf)

  • Hatching (48-72 hpf)

  • Larval stages (3-30 dpf)

  • Juvenile and adult stages

• Quantitative analysis: Perform Western blot analysis of whole embryo/larva lysates at each stage, with quantitative densitometry normalized to housekeeping proteins.

• Spatial analysis: Combine with whole-mount immunofluorescence or immunohistochemistry on sections to determine tissue-specific expression patterns at each stage.

• Comparison with transcription: Correlate protein expression data with available RNA-seq or in situ hybridization data to identify potential post-transcriptional regulation.

This approach is similar to developmental expression analyses performed for other zebrafish proteins and would provide crucial information about the potential roles of si:dkey-20i6.3 during development.

What are the most common causes of false positives/negatives when using si:dkey-20i6.3 antibody, and how can I address them?

Common issues with si:dkey-20i6.3 antibody detection and their solutions:

False Positives:

• Cross-reactivity: The polyclonal nature of the antibody may lead to binding to similar epitopes in other proteins.

  • Solution: Validate with knockout/knockdown controls. Perform peptide competition assays.

• Non-specific binding: High antibody concentrations can increase background.

  • Solution: Optimize antibody dilution. Use more stringent washing steps.

• Secondary antibody issues: Non-specific binding of secondary antibody.

  • Solution: Include secondary-only controls. Use serum from the same species as the secondary antibody in blocking solution.

False Negatives:

• Epitope masking: Fixation or sample preparation may alter epitope accessibility.

  • Solution: Try different fixation methods. Test antigen retrieval techniques.

• Protein degradation: Target protein may be degraded during sample preparation.

  • Solution: Use fresh samples. Add protease inhibitors to all buffers.

• Low expression levels: Target protein may be expressed at levels below detection threshold.

  • Solution: Use more sensitive detection methods. Concentrate proteins before analysis.

• Batch variation: Different lots of polyclonal antibodies may have different specificities.

  • Solution: Test each new lot against a known positive control.

Implementing these troubleshooting approaches will help ensure reliable results when working with the si:dkey-20i6.3 antibody.

How can I quantitatively validate the specificity and sensitivity of the si:dkey-20i6.3 antibody for my experimental system?

To quantitatively validate the si:dkey-20i6.3 antibody for your specific experimental system:

• Genetic validation:

  • Using morpholino knockdown or CRISPR/Cas9 knockout samples in Western blot to confirm band disappearance

  • Quantify signal reduction in knockdown vs. control samples

• Overexpression validation:

  • Create transgenic lines overexpressing si:dkey-20i6.3 with or without epitope tags

  • Confirm increased signal intensity correlates with expression level

  • Compare detection with tag-specific antibodies versus si:dkey-20i6.3 antibody

• Dose-response curve:

  • Create standard curves using recombinant protein to determine detection limits

  • Calculate the limit of detection (LOD) and limit of quantification (LOQ)

• Peptide competition assay:

  • Pre-incubate antibody with increasing concentrations of immunizing peptide

  • Plot dose-dependent reduction in signal intensity

• Cross-reactivity assessment:

  • Test against related zebrafish proteins (if available)

  • Determine percent cross-reactivity through quantitative analysis

• Reproducibility analysis:

  • Perform repeated measurements on identical samples

  • Calculate coefficient of variation (CV) to assess precision

A thorough validation using these quantitative approaches will establish confidence in the antibody's performance in your specific experimental context.

How does antibody-based detection of si:dkey-20i6.3 compare with RNA-based methods like in situ hybridization?

Comparing antibody-based detection with RNA-based methods for si:dkey-20i6.3:

For comprehensive analysis, researchers should consider using both approaches complementarily. RNA-based methods can provide information about transcriptional regulation, while antibody-based detection reveals the actual presence and localization of the protein. This combined approach is particularly valuable for uncharacterized proteins like si:dkey-20i6.3, where discrepancies between mRNA and protein levels might reveal important regulatory mechanisms.

When should I choose mass spectrometry over antibody-based detection for si:dkey-20i6.3 research?

Choose mass spectrometry over antibody-based detection in the following scenarios:

• Protein modifications: When investigating post-translational modifications of si:dkey-20i6.3, mass spectrometry can identify specific modification sites and types.

• Interaction discovery: For unbiased identification of protein interaction partners without prior knowledge, as mass spectrometry can detect all proteins in a complex.

• Isoform discrimination: When needing to distinguish between highly similar protein isoforms that might share antibody epitopes.

• Absolute quantification: When precise quantification of protein levels is required, using approaches like Selected Reaction Monitoring (SRM).

• No validated antibody: If current antibodies show inconsistent results or poor specificity.

• Multiplexed analysis: When analyzing many proteins simultaneously, as mass spectrometry can detect thousands of proteins in a single experiment.

• In situ protein localization studies

• High-throughput screening

• Routine protein detection when antibodies are well-validated

• Applications requiring intact cells or tissues

The optimal approach often combines both methods, using mass spectrometry for discovery and antibody-based methods for targeted validation and localization studies.